Meet the Data: Conversations with Leading Experts on the Role of HCC and Immunotherapy
SIO Meet the Data Series: Explore the evolving landscape of hepatocellular carcinoma treatment in this four-part podcast series, featuring conversations with leading experts on the role of immunotherapy. This series features expert discussions highlighting emerging clinical trial evidence and addressing key knowledge gaps relevant to the implementation of these novel therapeutic regimens into clinical practice.

Episode 1: Local Therapy vs. Combination (Local + Systemic) Therapy Synopsis

Should combination therapies redefine the standard of care in liver cancer? Experts Lingling Du and Christopher Malone examine the latest clinical evidence and debate the benefits and challenges of combining treatment modalities. Moderated by Edward Kim with Co-Moderator Cynthia De la Garza, the discussion analyzes efficacy, toxicity, cost, and patient selection criteria to determine which patients may benefit most from combination approaches.

Moderator:
• Edward Kim, MD | Mount Sinai

Co-Moderator:
• Cynthia De la Garza, MD | Mayo Clinic

Faculty:
• Lingling Du, MD | Ochsner Health
• Christopher Malone, MD | WashU Medicine

Resources

Dr. Lingling Du, MD

https://www.ochsner.org/doctors/lingling-du/

Dr. Christopher Malone, MD

https://physicians.wustl.edu/items/chris-malone/

IMbrave050 Trial:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00800-6/fulltext

LEAP-012 Trial:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract

Rowan Study:

https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.TPS622

Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma:

https://gut.bmj.com/content/gutjnl/68/2/335.full.pdf

Disclaimer

This discussion is intended for healthcare professionals for educational purposes only. It does not constitute medical advice and should not replace individualized patient care decisions.